We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk, seeking to remain in the front of the weight loss drug race, has inked a deal with EraCal Therapeutics, a biotech startup, whose small molecule program offers a potential novel mechanism of action for controlling appetite and obesity. Read More
Sanofi and Inhibrx, a clinical-stage biopharmaceutical company focused on developing a pipeline of novel biologic therapeutic candidates, today announced a $2 billion agreement for Sanofi to acquire Inhibrx. Read More
High drug prices and barriers to generic drugs are the targets of Sens. Amy Klobuchar (D-Minn.) and Bernie Sanders (I-Vt.) who are seeking answers from pharmaceutical manufacturers. Read More
Recently introduced bicameral, bipartisan legislation could make it easier for competitors to enter the generic and biosimilar market by putting controls on patent thickets created by pharmaceutical companies. Read More
To address the ongoing U.S. shortages of Bicillin L-A, a drug used to treat syphilis, the FDA has temporarily approved French manufacturer Laboratoires Delbert to import 3.6 million units of Extencilline, (benzathine benzylpenicillin) a drug not approved by the FDA, but also used to treat syphilis. Read More
Boston Scientific, GSK and Johnson & Johnson have each announced billion dollar acquisitions this week with major deals designed to expand the companies’ portfolios in very specific areas. Read More
Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Read More
Just days after the FTC won a temporary injunction to halt IQVIA’s proposed acquisition of Propel Media’s DeepIntent healthcare advertising business, the companies have mutually agreed to abandon the proposed merger. Read More